Loading
A phase 2 trial of durvalumab, pembrolizumab, sintilimab and other drugs with radiotherapy in gallbladder cancer and other biliary tract cancers, run by Shanghai Zhongshan Hospital, not yet recruiting.
Consolidative Radiotherapy (CSRT) in Patients With Oligometastatic/Locally Advanced Unresectable Bilary Tract Cancer (BTC) is a phase 2, randomised interventional study registered as NCT06502080 by Shanghai Zhongshan Hospital, with a registry enrolment figure of 128 participants, started 2024-07 and due to reach its primary completion in 2027-06-30. Interventions recorded: Consolidative radiotherapy, Standard-of-care systemic therapy: Gemcitabine + cisplatin/oxaliplatin + Durvalumab/Pembrolizumab/Sintilimab/Toripalimab. Conditions listed: Biliary Tract Cancer. Sites: China. No results are recorded here; the registry entry is the source.
Shares Gallbladder cancer in biliary tract cancer trials (eligibility and subgroups), Biliary tract cancer (all types), Durvalumab, Gemcitabine and the tag gallbladder-deep-dive.
Shares Sintilimab, Radiotherapy, Gallbladder cancer in biliary tract cancer trials (eligibility and subgroups), Biliary tract cancer (all types) and the tag gallbladder-deep-dive.
Shares Gallbladder cancer in biliary tract cancer trials (eligibility and subgroups), Biliary tract cancer (all types), Durvalumab, Gemcitabine and the tag gallbladder-deep-dive.
Shares Gallbladder cancer in biliary tract cancer trials (eligibility and subgroups), Biliary tract cancer (all types), Durvalumab, Gemcitabine and the tag gallbladder-deep-dive.
Shares Gallbladder cancer in biliary tract cancer trials (eligibility and subgroups), Biliary tract cancer (all types), Durvalumab, Gemcitabine and the tag gallbladder-deep-dive.
Shares Toripalimab, Oxaliplatin, Gallbladder cancer in biliary tract cancer trials (eligibility and subgroups), Biliary tract cancer (all types) and the tag gallbladder-deep-dive.
Shares Gallbladder cancer in biliary tract cancer trials (eligibility and subgroups), Biliary tract cancer (all types), Durvalumab, Gemcitabine and the tag gallbladder-deep-dive.
Shares Gallbladder cancer in biliary tract cancer trials (eligibility and subgroups), Biliary tract cancer (all types), Gemcitabine, Biliary tract cancer (cholangiocarcinoma) and the tag gallbladder-deep-dive.